Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
fda
4
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
4
×
san diego top stories
clinical trials
san francisco blog main
san francisco top stories
akcea therapeutics
alnylam pharmaceuticals
boston
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
drugs
hereditary transthyretin amyloidosis
indiana blog main
indiana top stories
inotersen
national
onpattro
patisiran
pfizer
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
tafamidis
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
andrew fire
What
drug
4
×
fda
medicine
4
×
alnylam
approved
cancer
rnai
afternoon
alnylam’s
approves
cells
deeper
dna
eisai
ema
employ
europe
fingerprint
flags
follows
gene
genetic
gets
going
harmful
higher
history
hits
incidence
interference
landmark
lorcaserin
loss
make
making
market
marketing
matter
method
mute
Language
unset
Current search:
fda
×
drug
×
medicine
×
" san diego blog main "
×
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug